vs

Side-by-side financial comparison of PHOTRONICS INC (PLAB) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

PHOTRONICS INC is the larger business by last-quarter revenue ($210.4M vs $140.6M, roughly 1.5× VERACYTE, INC.). VERACYTE, INC. runs the higher net margin — 29.3% vs 10.9%, a 18.4% gap on every dollar of revenue. On growth, VERACYTE, INC. posted the faster year-over-year revenue change (18.5% vs -5.5%). VERACYTE, INC. produced more free cash flow last quarter ($48.8M vs $25.2M). Over the past eight quarters, VERACYTE, INC.'s revenue compounded faster (20.5% CAGR vs -3.8%).

Photronics, Inc. is an American semiconductor photomask manufacturer. It was the third largest photomask supplier globally as of 2009. Photronics is a member of the eBeam Initiative.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

PLAB vs VCYT — Head-to-Head

Bigger by revenue
PLAB
PLAB
1.5× larger
PLAB
$210.4M
$140.6M
VCYT
Growing faster (revenue YoY)
VCYT
VCYT
+24.0% gap
VCYT
18.5%
-5.5%
PLAB
Higher net margin
VCYT
VCYT
18.4% more per $
VCYT
29.3%
10.9%
PLAB
More free cash flow
VCYT
VCYT
$23.6M more FCF
VCYT
$48.8M
$25.2M
PLAB
Faster 2-yr revenue CAGR
VCYT
VCYT
Annualised
VCYT
20.5%
-3.8%
PLAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
PLAB
PLAB
VCYT
VCYT
Revenue
$210.4M
$140.6M
Net Profit
$22.9M
$41.1M
Gross Margin
33.7%
72.5%
Operating Margin
22.9%
26.4%
Net Margin
10.9%
29.3%
Revenue YoY
-5.5%
18.5%
Net Profit YoY
-32.4%
704.8%
EPS (diluted)
$0.39
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PLAB
PLAB
VCYT
VCYT
Q4 25
$140.6M
Q3 25
$210.4M
$131.9M
Q2 25
$211.0M
$130.2M
Q1 25
$212.1M
$114.5M
Q4 24
$222.6M
$118.6M
Q3 24
$211.0M
$115.9M
Q2 24
$217.0M
$114.4M
Q1 24
$216.3M
$96.8M
Net Profit
PLAB
PLAB
VCYT
VCYT
Q4 25
$41.1M
Q3 25
$22.9M
$19.1M
Q2 25
$8.9M
$-980.0K
Q1 25
$42.9M
$7.0M
Q4 24
$33.9M
$5.1M
Q3 24
$34.4M
$15.2M
Q2 24
$36.3M
$5.7M
Q1 24
$26.2M
$-1.9M
Gross Margin
PLAB
PLAB
VCYT
VCYT
Q4 25
72.5%
Q3 25
33.7%
69.2%
Q2 25
36.9%
69.0%
Q1 25
35.6%
69.5%
Q4 24
37.0%
66.4%
Q3 24
35.6%
68.2%
Q2 24
36.5%
68.1%
Q1 24
36.6%
64.5%
Operating Margin
PLAB
PLAB
VCYT
VCYT
Q4 25
26.4%
Q3 25
22.9%
17.4%
Q2 25
26.4%
-4.0%
Q1 25
24.6%
2.5%
Q4 24
25.1%
3.5%
Q3 24
24.7%
10.4%
Q2 24
25.8%
4.0%
Q1 24
26.6%
-4.8%
Net Margin
PLAB
PLAB
VCYT
VCYT
Q4 25
29.3%
Q3 25
10.9%
14.5%
Q2 25
4.2%
-0.8%
Q1 25
20.2%
6.2%
Q4 24
15.2%
4.3%
Q3 24
16.3%
13.1%
Q2 24
16.7%
5.0%
Q1 24
12.1%
-1.9%
EPS (diluted)
PLAB
PLAB
VCYT
VCYT
Q4 25
$0.50
Q3 25
$0.39
$0.24
Q2 25
$0.15
$-0.01
Q1 25
$0.68
$0.09
Q4 24
$0.54
$0.07
Q3 24
$0.55
$0.19
Q2 24
$0.58
$0.07
Q1 24
$0.42
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PLAB
PLAB
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$575.8M
$362.6M
Total DebtLower is stronger
$16.0K
Stockholders' EquityBook value
$1.1B
$1.3B
Total Assets
$1.8B
$1.4B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PLAB
PLAB
VCYT
VCYT
Q4 25
$362.6M
Q3 25
$575.8M
$315.6M
Q2 25
$558.4M
$219.5M
Q1 25
$642.2M
$186.1M
Q4 24
$640.7M
$239.1M
Q3 24
$606.4M
$274.1M
Q2 24
$559.9M
$235.9M
Q1 24
$521.5M
$209.2M
Total Debt
PLAB
PLAB
VCYT
VCYT
Q4 25
Q3 25
$16.0K
Q2 25
$19.0K
Q1 25
$21.0K
Q4 24
$25.0K
Q3 24
$28.0K
Q2 24
$2.5M
Q1 24
$2.7M
Stockholders' Equity
PLAB
PLAB
VCYT
VCYT
Q4 25
$1.3B
Q3 25
$1.1B
$1.3B
Q2 25
$1.1B
$1.2B
Q1 25
$1.1B
$1.2B
Q4 24
$1.1B
$1.2B
Q3 24
$1.1B
$1.2B
Q2 24
$1.0B
$1.1B
Q1 24
$1.0B
$1.1B
Total Assets
PLAB
PLAB
VCYT
VCYT
Q4 25
$1.4B
Q3 25
$1.8B
$1.4B
Q2 25
$1.7B
$1.3B
Q1 25
$1.7B
$1.3B
Q4 24
$1.7B
$1.3B
Q3 24
$1.6B
$1.3B
Q2 24
$1.6B
$1.2B
Q1 24
$1.6B
$1.2B
Debt / Equity
PLAB
PLAB
VCYT
VCYT
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PLAB
PLAB
VCYT
VCYT
Operating Cash FlowLast quarter
$50.1M
$52.6M
Free Cash FlowOCF − Capex
$25.2M
$48.8M
FCF MarginFCF / Revenue
12.0%
34.7%
Capex IntensityCapex / Revenue
11.8%
2.7%
Cash ConversionOCF / Net Profit
2.19×
1.28×
TTM Free Cash FlowTrailing 4 quarters
$64.5M
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PLAB
PLAB
VCYT
VCYT
Q4 25
$52.6M
Q3 25
$50.1M
$44.8M
Q2 25
$31.5M
$33.6M
Q1 25
$78.5M
$5.4M
Q4 24
$68.4M
$24.5M
Q3 24
$75.1M
$30.0M
Q2 24
$76.5M
$29.6M
Q1 24
$41.5M
$-9.0M
Free Cash Flow
PLAB
PLAB
VCYT
VCYT
Q4 25
$48.8M
Q3 25
$25.2M
$42.0M
Q2 25
$-29.1M
$32.3M
Q1 25
$43.3M
$3.5M
Q4 24
$25.2M
$20.4M
Q3 24
$50.7M
$27.7M
Q2 24
$56.5M
$26.8M
Q1 24
$-1.8M
$-11.1M
FCF Margin
PLAB
PLAB
VCYT
VCYT
Q4 25
34.7%
Q3 25
12.0%
31.8%
Q2 25
-13.8%
24.8%
Q1 25
20.4%
3.1%
Q4 24
11.3%
17.2%
Q3 24
24.0%
23.9%
Q2 24
26.0%
23.4%
Q1 24
-0.8%
-11.5%
Capex Intensity
PLAB
PLAB
VCYT
VCYT
Q4 25
2.7%
Q3 25
11.8%
2.1%
Q2 25
28.7%
1.0%
Q1 25
16.6%
1.6%
Q4 24
19.4%
3.5%
Q3 24
11.6%
1.9%
Q2 24
9.2%
2.4%
Q1 24
20.0%
2.2%
Cash Conversion
PLAB
PLAB
VCYT
VCYT
Q4 25
1.28×
Q3 25
2.19×
2.34×
Q2 25
3.55×
Q1 25
1.83×
0.76×
Q4 24
2.02×
4.80×
Q3 24
2.18×
1.98×
Q2 24
2.11×
5.16×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PLAB
PLAB

High End Integrated Circuits$53.6M25%
High End Flat Panel Displays$53.5M25%
KR$43.7M21%
Other$42.1M20%
Mainstream Flat Panel Displays$9.1M4%
Transferred At Point In Time$8.4M4%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons